CL2016000182A1 - Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación - Google Patents

Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación

Info

Publication number
CL2016000182A1
CL2016000182A1 CL2016000182A CL2016000182A CL2016000182A1 CL 2016000182 A1 CL2016000182 A1 CL 2016000182A1 CL 2016000182 A CL2016000182 A CL 2016000182A CL 2016000182 A CL2016000182 A CL 2016000182A CL 2016000182 A1 CL2016000182 A1 CL 2016000182A1
Authority
CL
Chile
Prior art keywords
granules
pharmaceutical composition
rifapentin
isoniazid
preparation process
Prior art date
Application number
CL2016000182A
Other languages
English (en)
Inventor
Khullar Praveen
Prajapati Dilip
Prasad Kum
Kumar Ramesh
Kumar Shakti
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51211797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000182(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2016000182A1 publication Critical patent/CL2016000182A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSICION FARMACEUTICA ORAL DE DOSIS FIJA EN FORMA DE UN COMPRIMIDO RECUBIERTO PARA TRATAR TUBERCULOSIS QUE COMPRENDE: A) GRANULOS QUE COMPRENDEN ISONIAZID Y UN EXCIPIENTE INTRAGRANULAR, B) GRANULOS QUE COMPRENDEN RIFAPENTINA Y UN EXCIPIENTE INTRAGRANULAR Y C) AL MENOS UN EXCIPIENTE INTRAGRANULAR; Y PROCESO PARA PREPARARLA.
CL2016000182A 2013-07-26 2016-01-22 Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación CL2016000182A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3341CH2013 2013-07-26

Publications (1)

Publication Number Publication Date
CL2016000182A1 true CL2016000182A1 (es) 2016-06-24

Family

ID=51211797

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000182A CL2016000182A1 (es) 2013-07-26 2016-01-22 Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación

Country Status (18)

Country Link
US (1) US20160158157A1 (es)
EP (1) EP3024443A1 (es)
JP (1) JP6461142B2 (es)
CN (1) CN105407875A (es)
AU (1) AU2014295098B2 (es)
CA (1) CA2918827A1 (es)
CL (1) CL2016000182A1 (es)
EC (1) ECSP16005208A (es)
HK (1) HK1218862A1 (es)
IL (1) IL243368A0 (es)
MX (1) MX2016001154A (es)
PE (1) PE20160520A1 (es)
PH (1) PH12016500120A1 (es)
RU (1) RU2682178C2 (es)
SG (2) SG10201800447UA (es)
TW (1) TWI651084B (es)
WO (1) WO2015011161A1 (es)
ZA (1) ZA201600109B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918828A1 (en) 2013-07-26 2015-01-29 Sanofi Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation
SG11201510732VA (en) 2013-07-26 2016-01-28 Sanofi Sa Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
CN114306247B (zh) * 2020-09-27 2026-03-06 江苏先声药业有限公司 一种含利福喷汀药物组合物及其制备方法
CN115944638A (zh) * 2022-12-26 2023-04-11 卓和药业集团股份有限公司 一种利福喷丁和左氧氟沙星的复方双层片

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217912A (zh) * 1997-11-26 1999-06-02 岑冠新 复方利福喷丁制剂及制备方法
KR100620404B1 (ko) * 2000-08-09 2006-09-13 파나세아 바이오테크 리미티드 항결핵 약물의 신규 약제학적 조성물 및 그의 제조방법
WO2002087547A1 (en) * 2001-04-27 2002-11-07 Lupin Limited An improved process for preparation of four-drug anti-tubercular fixed dose combination
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US20090295921A1 (en) * 2005-10-12 2009-12-03 Pioneer Corporation Vehicle-mounted photographing device and method of measuring photographable range of vehicle-mounted camera
CN1857280A (zh) * 2006-04-11 2006-11-08 济南帅华医药科技有限公司 一种复方抗结核药物缓释制剂
KR101197277B1 (ko) * 2009-02-05 2012-11-05 (주) 벡스코아 경구용 결핵의 치료용 또는 예방용 고형 제형
US8470365B2 (en) * 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom

Also Published As

Publication number Publication date
RU2016106384A (ru) 2017-08-29
ZA201600109B (en) 2017-04-26
AU2014295098A1 (en) 2016-02-11
RU2682178C2 (ru) 2019-03-15
AU2014295098B2 (en) 2019-07-11
CA2918827A1 (en) 2015-01-29
HK1218862A1 (zh) 2017-03-17
PE20160520A1 (es) 2016-05-31
JP6461142B2 (ja) 2019-01-30
EP3024443A1 (en) 2016-06-01
JP2016539109A (ja) 2016-12-15
US20160158157A1 (en) 2016-06-09
CN105407875A (zh) 2016-03-16
SG10201800447UA (en) 2018-02-27
TWI651084B (zh) 2019-02-21
ECSP16005208A (es) 2017-02-24
TW201605442A (zh) 2016-02-16
MX2016001154A (es) 2016-04-29
IL243368A0 (en) 2016-02-29
WO2015011161A1 (en) 2015-01-29
SG11201510730UA (en) 2016-01-28
PH12016500120A1 (en) 2016-04-25
RU2016106384A3 (es) 2018-05-31

Similar Documents

Publication Publication Date Title
DOP2017000306A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
EA201500742A1 (ru) Защищенные от нецелевого использования фармацевтические композиции
MX2016013236A (es) Formulacion inmunosupresora.
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
CY1122387T1 (el) Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
MX2020004107A (es) Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas.
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
AR110374A1 (es) Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación
AR109693A1 (es) Formulaciones de liberación inmediata de oprozomib
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
UA116011C2 (uk) Частинки фенілефрину резинату та їх використання у фармацевтичних композиціях
IN2013MU02110A (es)
UA97982U (uk) Лікарський засіб седативної дії у вигляді таблеток